Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

[Image: see text] GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy o...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:ACS Pharmacol Transl Sci
Main Authors: Wang, Vicki, Kuo, Tung-Tai, Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Chou, Yu-Ching, Fu, Zhao-Yang, Lai, Li-Wen, Jung, Jin, Choi, Hoi-II, Choi, Doo-Sup, Li, Yazhou, Olson, Lars, Greig, Nigel H., Hoffer, Barry J., Chen, Yuan-Hao
Format: Artigo
Sprog:Inglês
Udgivet: American Chemical Society 2021
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033754/
https://ncbi.nlm.nih.gov/pubmed/33860208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.1c00013
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker